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EDITORIAL
Early cancer diagnosis: reaching targets across whole
populations amidst setbacks
Early diagnosis of cancer, followed by timely and appropriate therapy, are the cornerstones of the secondary prevention of cancer,
thus the NHS has set a 2028 target to achieve 75% early stage (TNM I/II) at cancer diagnosis. In this context, Barclay et al. evaluated
overall, sex, age and deprivation-group-specific progress towards this target based on 202,000 cancer patients diagnosis in 2015.
Herein, we discuss their findings which form a valuable pre-COVID-19 pandemic status. We discuss the impact of the pandemic and
the efforts being made in innovative early detection and diagnosis research.
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MAIN
Progress in the co-important secondary prevention elements of
early diagnosis and successful treatment have paved the way for
the doubling of cancer survival and improved quality of life in
cancer survivors in high income countries over the past few
decades. Because early diagnosis is an essential enabler of curative
treatment, in its Long Term Plan the UK NHS set a target to
achieve 75% early stage (TNM stage I/II) cancer by 2028. It is within
this context that Barclay, Lyratzopoulos and colleagues1 evaluated
overall and socio-demographic group-specific progress towards
this target among 202,000 cancer patients diagnosed with 10
common solid cancers in England in 2015. In this robust analysis,
57% of patients were diagnosed at early stages, i.e., 18 absolute
percentage points (pp) short of the target. The analysis specifically
quantified the extent of inequities associated with deprivation,
older age (>65 years) and sex (for most cancers, men had later
stage than women), and predicted that, beyond the potential
elimination of these inequities, there would still be a 14-pp
shortfall from the NHS target. However, this overall picture varied
immensely by cancer type: bladder, breast, endometrial and
melanoma had reached the 75% early stage target in 2015, renal
and prostate cancers were a few percentage points under 60%,
colon and rectal 43–45% and ovary and lung under 30%.
The findings identify demographic groups needing specific
attention to improve early stage at diagnosis, including male
and older age groups for renal cancer, more deprived groups for
colon and rectal, older and deprived groups for ovary and
prostate and men for lung cancer. For prostate cancer, they
found that addressing inequities linked to deprivation would
result in a 9.1% absolute increase in the percentage of patients
diagnosed with stage I/II cancer.1 This is substantial, but also
demonstrates how, in the absence of clear evidence for a
prostate cancer screening programme, that socioeconomic
differences in cancer awareness and men self-referring for
routine prostate-specific antigen testing, is likely to be contribut-
ing to widening inequities in prostate cancer outcomes.2
Addressing this gap will therefore not be straightforward.
Across the 10 cancers, the inequities linked to older age
contributed to the greatest percentage (5.1%) of the 2015 late
stage cancers, followed by inequities linked to deprivation
(2.7%), then sex (2.0%). This older population will need further
attention as the growing cancer burden predicted in the UK is
largely due to the growing and ageing population.3 Further-
more, age gaps in survival already exist.4
These 2015 findings must now be put into perspective of the
current major upheaval in cancer care. In a year when the severe
acute respiratory syndrome Coronavirus-2 (COVID-19) pandemic has
severely disrupted lives, movement, health seeking behaviours and
health systems in England and beyond, the present article1 provides
a comprehensive benchmark of the pre-pandemic status. In the UK,
following commencement of national COVID-19 pandemic lock-
down measures (16 March 2020), cancer screening was suspended,
routine referral deferred or cancelled and large declines in the 2-
week-wait urgent referrals for diagnostic workup of suspected
cancers were observed. For example, in England, between March
and August 2020, there were 14,000 fewer referrals for suspected
lung cancer, i.e., 60% of pre-lockdown referrals, probably because of
the similarity of initial symptoms with those for mild COVID-19.5
Declines in referrals were not restricted to lung cancer, but were
seen for several cancer types. Fewer diagnostic investigations were
also observed, with endoscopy activity in the period up to the end
of May 2020 reduced to 12% of pre-COVID levels.6 This decrease in
referrals and in diagnostic investigation implies an eventual later
diagnosis and possible reversal or at most stagnation of progress to
achieve earlier stage at diagnosis at the population level.
Whilst it is too early to assess this pandemic’s impact on cancer
survival due to delays in diagnosis and treatment, modelling studies
provide valuable assessments of the potential excess deaths. Using a
route-to-diagnosis framework, Maringe et al.7 have estimated the
impact of pandemic lockdown measures and changes in patient
behaviour and availability of services for breast, colorectal, lung and
oesophageal cancer. They modelled a shift from diagnoses via
routine routes, including routine workup and screening, to the
urgent 2-week-wait or emergency referrals operating at varying
capacity levels, and found between 7.9 to 9.6% more deaths for
breast, ~16% for colorectal, ~5% for lung and 6% for oesophageal
cancer. In total, over 3300 additional COVID-19 delay-related deaths
would occur for these four cancers, equating to ~60,000 years of life
lost due to avoidable deaths. These results are considered
conservative as they only refer to four tumour types and do not
account for the impact of treatment delay or sub-optimal treatment
delivery on mortality.8
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During the pandemic’s upheaval, the 2015 socio-demographic
groups who were more vulnerable to a later cancer diagnosis need
to be paid particular attention to avert yet further disadvantage.
Some of these groups, notably the elderly and the most deprived,
may also be disproportionately affected by further late cancer
diagnosis through their greater probability of lockdowns and
shielding put in place to protect against COVID-19 mortality risks.
The situation is likely to be exacerbated by a failure to provide public
health messaging that accurately conveys the magnitude of risks of
severe illness from COVID-19 infection compared with the risks of
not seeking healthcare advice if symptomatic from cancer. In
addition, changes in health seeking behaviour and the increasing
necessity to self-navigate a complex and dynamically changing
healthcare system (e.g. increasing remote consultations) could
widen gaps in individuals receiving timely access to diagnostic
services and cancer treatment. For example, there has also been a
change in the geographical provision of access to services due to
the creation of COVID-19 free surgical pathways,9 with previous
studies demonstrating a differential impact of increasing travel
burden on access to cancer treatment for individuals from lower
socioeconomic groups.10 Similarly, the welfare impacts of rising
unemployment and income inequality from the COVID-19 pandemic
may disproportionately impact on lower socioeconomic groups and
has been associated with rises in cancer mortality following previous
economic downturns.11 In short, the COVID-19 pandemic will have
undoubtedly hindered progress towards the 2028 target of 75% of
cancers diagnosed at early stages, but actions to achieve a recovery
should be expected and prioritised. When possible, an updated
comparative analysis of Barclay et al.’s 2015 situation to a period
including and beyond the pandemic will be informative.
Notwithstanding, even had the pandemic not occurred, further
improvements in early stage at cancer diagnosis are needed and
Barclay et al.’s analysis1 demonstrates that these are unlikely to be
achieved through addressing inequities via the current routes of
diagnosis alone. To this end, the Cancer Research UK Early Detection
and Diagnosis Roadmap Steering Group have highlighted the need
for a paradigm shift in cancer early diagnosis.12,13 The detailed
roadmap calls for a more unified multi-disciplinary and multi-sector
effort to advance cancer early detection and diagnosis. It outlines a
range of avenues for investigation to aid early diagnosis—from
cancer biology, including precancer evolution and circulating
tumour DNA, to risk prediction models, artificial intelligence, modern
technological advances and finally commercialisation of products for
scale-up and community reach. This roadmap holds a promising
future for the early detection and diagnosis of cancer, advances that
should be designed and subsequently evaluated to reach the entire
population and especially demographic groups prone to late
diagnosis.
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